A perfect four-quarter earnings beat run with an average surprise of nearly 15%, strong 18% margins, and a high Piotroski score underpin a high-quality franchise that currently trades roughly 25% below the analyst consensus target — offering a risk/reward of approximately 4.6-to-1 in the buyer's favor — but a death cross is in place, the stock is in a confirmed downtrend with RSI near oversold, and 93% licensing concentration adds structural risk; timing is the primary near-term obstacle to expressing this value.
Thesis pillars
- High Quality Margins And Financials→Stable
- Perfect Earnings Beat Streak→Stable
- Attractive Risk Reward Geometry→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Nov 18, 2025
Dolby Laboratories (DLB) Stock Analysis
Breakout setup · Catalyst-Driven edge
Industrials · Specialty Business Services
Sell if holding. At $62.91, A.R:R 0.8:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: licensing (93.0%); Concentration risk — Supplier: sole source suppliers.
Dolby Laboratories licenses audio and video technologies — including Dolby Atmos, Dolby Vision, and audio codecs — to approximately 1,000 device manufacturers, generating 93% of fiscal 2025 revenue from licensing and 7% from cinema hardware and services. Per-unit royalties from... Read more
Sell if holding. At $62.91, A.R:R 0.8:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: licensing (93.0%); Concentration risk — Supplier: sole source suppliers. Chart setup: Golden cross, above all MAs, RSI 69, MACD bullish. Score 5.8/10, moderate confidence.
Passes 6/7 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 18d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
About Dolby Laboratories
About Dolby Laboratories
Dolby Laboratories derived 93% of fiscal 2025 revenue from licensing technology, brands, and patents to approximately 1,000 consumer electronics manufacturers globally. Broadcast markets (televisions and set-top boxes) represented 34% of licensing revenue in fiscal 2025, Mobile (smartphones and tablets) 22%, CE (Blu-ray, AVRs, soundbars) 12%, PC 12%, and Other markets including Dolby Cinema and Automotive 20%. The company held approximately 28,400 issued patents across more than 200 jurisdictions as of September 26, 2025, with 4,179 new patents issued in fiscal 2025.
Dolby earns licensing revenue through two channels: Branded Technology licensing (Dolby Atmos, Dolby Vision, DD+, and AC-4 codecs) sold to semiconductor manufacturers and OEMs under per-unit royalty, committed-volume, or fixed-fee arrangements, and Patent Licensing through pools administered by Access Advance, Sisvel, Via LA, and Vectis. Dolby holds majority ownership in Via LA alongside Philips and Mitsubishi. The licensing cycle typically runs in two stages — IC manufacturers embed Dolby technologies in chips, then OEM system manufacturers incorporate those chips and pay per-unit royalties. In fiscal 2025, Dolby shifted distribution of DD and DD+ codecs for Windows 11 24H2 PCs directly to PC OEMs, bypassing Microsoft's operating system channel. Products and services (7% of revenue) encompass cinema hardware including digital servers, audio processors, and amplifiers, plus Dolby Cinema box-office revenue-sharing. The company relies on sole source suppliers for certain components used in cinema hardware manufacturing.
Show full overview
Dolby's issued patents expire between 2025 and 2047, and licensing agreements generally require licensees to pay full royalties only while patents remain in force in relevant markets. If pool licensees determine that pooled patents lack sufficient aggregate value, they may not renew their agreements — a risk that applies across Access Advance, Sisvel, Via LA, and Vectis pools. With approximately 6,100 pending patent applications as of September 26, 2025, the company's revenue sustainability depends on continued successful patent prosecution and active participation in international standards bodies including ETSI, ISO, IEC, and ITU.
See also: Industrials · Specialty Business Services
From Dolby Laboratories's most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated 2026-10-30Recent Developments — Dolby Laboratories
Latest news
- NEWS Lazard Asset Management LLC Lowers Position in Dolby Laboratories $DLB - MarketBeat — MarketBeat neutral
- NEWS What To Expect From Dolby Laboratories’s (DLB) Q2 Earnings - StockStory — StockStory neutral
- NEWS What To Expect From Dolby Laboratories’s (DLB) Q2 Earnings - stockstory.org — stockstory.org neutral
- NEWS Vest Financial LLC Increases Stock Holdings in Dolby Laboratories $DLB - MarketBeat — MarketBeat positive
- NEWS Dolby Laboratories (DLB) Reports Q1: Everything You Need To Know Ahead Of Earnings - StockStory — StockStory neutral
Generated 2026-10-30T11:22:45Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductlicensing93%10-K Item 1: 'We generated 93% of our revenues in fiscal 2025 by licensing technology, brand, and patents'
- HIGHSuppliersole source suppliers10-K Item 1: 'we rely on sole source suppliers for certain components used to manufacture our products'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $62.91, A.R:R 0.8:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: licensing (93.0%); Concentration risk — Supplier: sole source suppliers. Chart setup: Golden cross, above all MAs, RSI 69, MACD bullish. Prior stop was $59.79. Score 5.8/10, moderate confidence.
Analyst target: $67.15 (+6.7% upside). Prior stop was $59.79. Stop-loss: $59.79.
Concentration risk — Product: licensing (93.0%); Concentration risk — Supplier: sole source suppliers; Thin upside margin: 6.7%.
Dolby Laboratories trades at a P/E of 26.8 (forward 13.7). TrendMatrix value score: 5.8/10. Verdict: Sell.
9 analysts cover DLB with a consensus score of 4.1/5. Average price target: $79.
What does Dolby Laboratories do?Dolby Laboratories licenses audio and video technologies — including Dolby Atmos, Dolby Vision, and audio codecs — to...
Dolby Laboratories licenses audio and video technologies — including Dolby Atmos, Dolby Vision, and audio codecs — to approximately 1,000 device manufacturers, generating 93% of fiscal 2025 revenue from licensing and 7% from cinema hardware and services. Per-unit royalties from OEMs across broadcast, mobile, PC, and CE device markets drive the licensing model. The company held approximately 28,400 issued patents as of September 26, 2025.